Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?

Researchers at the troubled Biogen are touting the latest safety update on a Phase III MS drug now under review at the FDA. Designed as a milder drug than its MS star Tecfidera, the company reported that there was a discontinuation rate of 0.7% over one year of treatment using diroximel fumarate, an oral therapy which they believe will help position this on the market in 2020.